...
首页> 外文期刊>Annals of epidemiology >The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: the Heart and Estrogen-Progestin Replacement Study (HERS).
【24h】

The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: the Heart and Estrogen-Progestin Replacement Study (HERS).

机译:绝经后激素治疗与血清尿酸和冠心病事件风险的关系:心脏和雌激素-孕激素替代研究(HERS)。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To determine whether baseline serum uric acid (UA) levels and estrogen-progestin (E+P)-associated change in serum UA in postmenopausal women with coronary disease are associated with recurrent coronary heart disease (CHD) events. METHODS: 2763 postmenopausal women enrolled in the Heart and Estrogen-Progestin Replacement Study (HERS) were randomly assigned to take conjugated E+P or placebo in a secondary CHD prevention study. The primary outcome for these analyses was nonfatal myocardial infarction or CHD death during a mean follow up of 4.1 years. RESULTS: The baseline serum UA for the cohort was 5.4 mg/dl and, compared with placebo, E+P on average lowered serum UA levels slightly (0.2 mg/dl) at one year of follow up (p<0.0001). Baseline serum UA levels were associated in simple proportional hazards models with CHD events; each standard deviation increase (1.3 mg/dl) was associated with a 22% increased risk of primary CHD events (p=.0001). This association, however, was no longer statistically significant after multivariable adjustment (p=0.36). There was no association between on-study change in serum UA level and any CHD outcome. CONCLUSION: Treatment with E+P lowered serum UA levels slightly, but neither baseline UA nor change in UA affected CHD risk.
机译:目的:确定绝经后患有冠心病的妇女的基线血清尿酸(UA)水平和雌激素-孕激素(E + P)相关的血清UA变化是否与复发性冠心病(CHD)事件相关。方法:参加心脏和雌激素-孕激素替代研究(HERS)的2763名绝经后妇女在第二项CHD预防研究中被随机分配接受联合E + P或安慰剂治疗。这些分析的主要结果是平均随访4.1年的非致命性心肌梗塞或冠心病死亡。结果:该人群的基线血清UA为5.4 mg / dl,与安慰剂相比,E + P在随访一年中平均平均略微降低了血清UA水平(0.2 mg / dl)(p <0.0001)。在简单比例风险模型中,基线血清UA水平与CHD事件相关。每次标准差增加(1.3 mg / dl)与原发性CHD事件发生风险增加22%(p = .0001)相关。但是,在进行多变量调整后,这种关联不再具有统计学意义(p = 0.36)。研究中血清UA水平的变化与任何冠心病预后之间没有关联。结论:E + P治疗可轻微降低血清UA水平,但基线UA或UA变化均不会影响CHD风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号